KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Donidalorsen for the Treatment of Hereditary Angioedema: A Review of Clinical Studies.

Marc A Riedl, Timothy Craig, William R Lumry, Laura Bordone, Sabrina Treadwell, Aaron Yarlas, Kenneth B Newman, Danny M Cohn

Drug Des Devel Ther 20 589693

PMID42415941
PMCIDPMC13340341
DOI10.2147/DDDT.S589693
发表日期2026-07-08
AI 判定该论文不进入自动 KM 提取:The record is a review of clinical studies, not a primary report of a Phase III RCT. The abstract mentions a Phase III RCT (OASIS-HAE) but this publication is a review article summarizing multiple studies.
摘要

摘要

Hereditary angioedema (HAE) is a rare disease characterized by recurrent attacks of severe tissue swelling caused by dysregulation of the kallikrein-kinin system. Donidalorsen is a triantennary N-acetyl galactosamine-conjugated antisense oligonucleotide designed to specifically and reversibly reduce plasma prekallikrein production by binding to plasma prekallikrein messenger RNA in the liver. This report reviews donidalorsen's mechanism of action and data on the pharmacodynamics, efficacy, patient-reported outcomes, and safety of donidalorsen from clinical trials in adolescent and adult participants. In a Phase 1 trial, subcutaneous (SC) administration of donidalorsen led to dose-dependent reductions in plasma prekallikrein concentrations. In a subsequent Phase 2, randomized, placebo-controlled study, donidalorsen 80 mg SC once every 4 weeks (Q4W) for 16 weeks resulted in a 90% mean reduction in monthly HAE attack rate vs placebo, which was sustained for up to 4 years in an open-label extension (OLE). In the Phase 3, randomized, placebo-controlled OASIS-HAE study, patients receiving donidalorsen 80 mg Q4W or once every 8 weeks (Q8W) experienced significant mean reductions in HAE attack rates vs placebo over Weeks 0 to 24 (Q4W: 81%; Q8W: 55%). Mean attack rates were reduced by 87% (Q4W) and 60% (Q8W) vs placebo over Weeks 4 to 24. Reductions in attack rate from OASIS-HAE baseline were sustained for up to 1 year in the OASISplus OLE (Q4W: 94%; Q8W: 95%). A notable study in the clinical program included a cohort of patients who switched from berotralstat, C1 inhibitor, or lanadelumab to donidalorsen for up to 1 year; mean attack rates were reduced by 68% vs baseline (on prior HAE prophylaxis). Donidalorsen treatment improved quality of life at all assessments. Across studies, donidalorsen had an acceptable safety and tolerability profile, with mostly mild to moderate adverse events reported. Overall, the clinical data are promising for donidalorsen as a long-term prophylactic medication for HAE.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。